Drug Type DNA vaccine, Therapeutic vaccine |
Synonyms CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine(EpiThany, Inc.), EP-101 |
Action inhibitors |
Mechanism CDH3 inhibitors(Cadherin 3 inhibitors), ENG inhibitors(endoglin inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic Triple-Negative Breast Carcinoma | Phase 2 | United States | 01 Dec 2025 | |
| PD-L1 negative Triple Negative Breast Cancer | Phase 2 | United States | 01 Dec 2025 | |
| HER2-negative breast cancer | Phase 2 | United States | 07 Nov 2025 | |
| Hormone Receptor Positive Breast Adenocarcinoma | Phase 2 | United States | 07 Nov 2025 | |
| Hormone receptor positive breast cancer | Phase 2 | United States | 07 Nov 2025 | |
| Hormone receptor positive HER2 negative breast cancer | Phase 2 | United States | 07 Nov 2025 | |
| Breast Cancer | Phase 1 | United States | 18 Aug 2022 |
NCT02157051 (SITC2022) Manual | Phase 1 | - | mkhvljvvvt(iugjxhiqbd) = tkoqzvnykm gpcydyybml (kdclbvycbg ) View more | Positive | 01 Nov 2022 |





